Press Releases
Search
-
22 Oct 2014
Business Review for the Nine Months Ended September 30, 2014
Solid growth in nine-month sales: Up 7.4%, including BioFire and at constant exchange rates Up 3.5% at constant exchange rates and scope of consolidation, in line with the full-year target The America...
-
10 Oct 2014
bioMérieux inaugurates a new multidisciplinary R&D center for infectious disease diagnostics
The R&D Center at La Balme-Les-Grottes is specialized in the development of new diagnostic solutions in microbiology: high medical value tests for improved patient care and fully automated solutions t...
-
18 Sep 2014
bioMérieux launches chromID® Salmonella Elite, the new generation of culture media for earlier detection of Salmonella strains in clinical fecal samples
Marcy l'Étoile, France – September 18, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the launch of chromID® Salmonella Elite, a new selective chromogen...
-
03 Sep 2014
bioMérieux - First-Half 2014 Results
Solid growth in first-half sales Up 7.9%, including BioFire and at constant exchange rates Up 4.2% at constant exchange rates and scope of consolidation 2014 financial objectives maintained Contributi...
-
23 Jul 2014
bioMérieux VIRTUO™, the new generation of blood culture system, is CE-marked
VIRTUO™ is the next dimension of blood culture microbial detection...
-
17 Jul 2014
bioMérieux - Second-Quarter 2014 Business Review
Solid growth in first-half sales Up 7.9%, including BioFire and at constant exchange rates Up 4.2% like-for-like*, in line with the target for the year Up 3.5% on a reported basis Greater disparity be...
-
28 May 2014
The General Shareholders’ Meeting of bioMérieux approves the appointment of two new independent directors
Marcy l’Etoile, France, May 28, 2014 - The General Meeting of Shareholders of bioMérieux, a world leader in the field of in vitro diagnostics, today approved the appointment of two new independent dir...
-
05 May 2014
BioFire’s FilmArray® Gastrointestinal Panel Receives FDA Clearance
Marcy l’Etoile, France - May 5, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire, its new molecular biology affiliate, received U.S. Food and Drug A...
-
23 Apr 2014
First-Quarter 2014 Business Review
Sales: Up 7.9%, including BioFire and at constant exchange rates Up 4.1% like-for-like*, in line with the target for the year Continued stabilization in Western Europe, up 1.4%* Sustained solid growth...
-
15 Apr 2014
Alexandre Mérieux Assumes Role of bioMérieux CEO
Marcy l’Etoile (France), April 15, 2014 - Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic pl...
-
19 Mar 2014
bioMérieux - 2013 Financial Results
HIGHLIGHTS Objectives met Solid financial performance Sales up 4.6% at constant exchange rates and scope of consolidation Operating income before non-recurring items: €262 million, or 16.5% of sales F...
-
26 Feb 2014
bioMérieux strengthens its Clostridium difficile offer with the launch of VIDAS® C. difficile GDH
VIDAS® C. difficile GDH is the 100th assay for use on VIDAS® range VIDAS® C. difficile GDH is the only FDA-approved automated immunoassay parameter for GDH* detection * Glutamate dehydrogenase...
-
19 Feb 2014
BioFire Submits 510(k) Application to FDA for FilmArray® Gastrointestinal Panel
BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The comprehensive FilmArra...
-
27 Jan 2014
Appointment of Claire Giraut as bioMérieux’s Corporate Vice President & Chief Financial Officer
Marcy l’Etoile, France, January 27, 2014 — bioMérieux, a world leader in the field of in vitro diagnostics, announces that Claire Giraut has been appointed Corporate Vice President & Chief Financial O...
-
22 Jan 2014
Business Review for the year ended December 31, 2013
2013: solid 4.6% organic growth in sales At the top end of the target range announced early in the year Faster organic growth in North America and firmer business in Western Europe Sustained fast grow...